Market Place
Sourcing Support
BMS wins FDA approval of $13B cardio drug mavacamten
29 Apr 2022 //
BIOPHARMADIVE
Evelo Biosciences names former Alnylam, MyoKardia CEOs as strategic advisors
21 Apr 2022 //
GLOBENEWSWIRE
Bristol Myers uncorks more winning data for blockbuster-potential heart drug
16 Feb 2022 //
ENDPTS
FDA delays its decision on Bristol Myers` $13B heart drug another three months
20 Nov 2021 //
ENDPTS
BMS` $13B MyoKardia heart drug gets along with beta blockers
13 Nov 2021 //
FIERCEBIOTECH
A couple months ahead of PDUFA data, BMS rolls out long-term data for mavacamten
13 Nov 2021 //
ENDPTS
LianBio inks $325M IPO for pipeline with BMS, BridgeBio, Lyra
01 Nov 2021 //
FIERCEBIOTECH
MyoKardia`s clinical ops lead jumps ship to Esker
20 Aug 2021 //
FIERCEBIOTECH
EXPLORER-HCM Trial finds substantial health status improvements with mavacamten
20 May 2021 //
PRWEB
FDA accepts Bristol Myers` pitch for former MyoKardia drug; Clovis` Rubraca aces
20 Mar 2021 //
ENDPTS
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s
17 Nov 2020 //
BUSINESSWIRE
MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM
14 Nov 2020 //
GLOBENEWSWIRE
MyoKardia Presents Mavacamten Clinical and Non-Clinical Data
13 Nov 2020 //
GLOBENEWSWIRE
MyoKardia Collab with the American College of Cardiology and PINNACLE/Veradigm
11 Nov 2020 //
GLOBENEWSWIRE
Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period
04 Nov 2020 //
BIOSPACE
MyoKardia Announces Multiple Abstracts Selected for Presentation
02 Nov 2020 //
GLOBENEWSWIRE
How MyoKardia got Bristol Myers to bump up its buyout to $13B
21 Oct 2020 //
FIERCE BIOTECH
BMS offers a premium to reel in MyoKardia`s cardio pipeline with a $13B buyout
06 Oct 2020 //
ENDPTS
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
06 Oct 2020 //
PRESS RELEASE
Bristol to Pay $13.1 Billion for Heart-Drug Maker MyoKardia
05 Oct 2020 //
WSJ
MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy
09 Sep 2020 //
PRESS RELEASE
MyoKardia`s mavacamten boosts heart function in phase 3, teeing up 2021 filing
30 Aug 2020 //
FIERCE BIOTECH
A hedge fund bets on a biotech startup to bring new drugs to China
11 Aug 2020 //
BIOPHARMADIVE
MyoKardia & LianBio Form Strategic Partnership to Develop and Mavacamten
11 Aug 2020 //
GLOBENEWSWIRE
MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten
03 Aug 2020 //
GLOBENEWSWIRE
MyoKardia Announces Receipt of Breakthrough Therapy from FDA for Mavacamten
23 Jul 2020 //
GLOBENEWSWIRE
MyoKardia to Presesnt Danicamtiv Data at European Society of Cardiology Meeting
18 Jun 2020 //
GLOBE NEWSWIRE
J&J jumps into gamma delta field with Lava collaboration; Myokardia guns for $605M raise
16 May 2020 //
ENDPTS
MyoKardia Announces Pricing of Public Offering of Common Stock
12 May 2020 //
PRESS RELEASE
MyoKardia Announces Primary and All Secondary Endpoints Met in Ph3 Mavacamten
11 May 2020 //
GLOBENEWSWIRE
Myokardia at inflection point as heart drug readout nears
09 Apr 2020 //
BIOPHARMADIVE
MyoKardia cuts heart stress signs in biomarker study
30 Mar 2020 //
FIERCE BIOTECH
